Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Osteo-P is a brand name that refers to different pharmaceutical products depending on the geographic region, most commonly identifying either alendronate sodium or a combination of calcium carbonate and cholecalciferol (vitamin D3). As alendronate, it is a second-generation bisphosphonate that acts as a potent inhibitor of osteoclast-mediated bone resorption by targeting the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway. This action increases bone mineral density and reduces fracture risk in patients with osteoporosis or Paget's disease. In other markets, such as the Philippines, Osteo-P is a widely used combination of calcium carbonate and vitamin D3, providing elemental calcium for bone mineralization and cholecalciferol to enhance intestinal calcium absorption via the vitamin D receptor. Both versions are primarily indicated for the management of osteoporosis and the prevention of bone density loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Osteo-P.